Neurobiologists successfully test novel drug principle in a mouse model and in brain organoids of ALS patients

A research team led by Prof. Dr. Hilmar Bading, neurobiologist at Heidelberg University, examined a neuroprotective molecule that belongs to a novel drug class. It is able to inhibit the interactions of certain proteins and has been successfully tested in a mouse model of amyotrophic lateral sclerosis (ALS) and in brain organoids of ALS patients.